References

  1. Aldenhoven M and Kurtzberg J. Cord blood is the optimal graft source for the treatment of pediatric patients with lysosomal storage diseases: clinical outcomes and future directions. Cytotheraphy 2015;17:765-74
  2. Ballen KK, Gluckman E, Broxmeyer HE. Umbilical cord blood transplantation: the first 25 years and beyond. Blood. 2013 May 14; 122: 491-498
  3. Ballen KK, Spitzer TR, Yeap B, Steve M, Dey BR, Attar E et al. Excellent disease-free survival after double cord blood transplantion using a reduced intensity chemotherapy only conditioning regimen in a diverse adult population. ASH Annual Meeting Abastracts 2005; 106: 2048.
  4. Barker J et al. Survival after transplantation of unrelated donor umbilical cord blood is comparable to that of human leukocyte antigen-matched unrelated donor bone marrow: results of a match-pair ana;ysis. Blood 2001;97:2957-61
  5. Barker JN, Weisdorf DJ, DeFor TE et al. Transplantion of 2 partially HLA matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood 2005; 105:1343-1347
  6. Bhatia M, Walters M. Hematopoietic cell transplantation for thalassemia and sickle cell disease: past, present and future. Bone Marrow Transplant, 2008; 41:109-17.
  7. Blum B1, Benvenisty N. The tumorigenicity of human embryonic stem cells. Adv Cancer Res. 2008;100:133-58
  8. Boelens JJ, Aldenhoven M, Purtill D,et al. Eurocord; Inborn Errors Working Party of European Blood and Marrow Transplant group; Duke University Blood and Marrow Transplantation Program; Centre for International Blood and Marrow Research. Outcomes of transplantation using various hematopoietic cell sources in children with Hurler syndrome after myeloablative conditioning. Blood. 2013;121:3981-7.
  9. Borlongan CV, Hadman M, Sanberg CD, Sanberg PR. Central nervous system entry of peripherally injected umbilical cord blood cells is not required for neuroprotection in stroke. 2004;10:2385–2389
  10. Broxmeyer H et al. Human umbilical cord blood as a potential source of transplantable hematopoietic stem/progenitor cells. PNAS 1989;86;3828-32
  11. Broxmeyer H, Lee M-R, Hangoc G, Cooper S, Prasain N, Kim Y-J, Mallett C, YE Z, Witting S, Cornetta K, Cheng K, Linzhao C, Yoder M. Hematopoietic stem/progenitor cells, generation of induced pluripotent stem cells and isolation of endothelial progenitors from 21-23.5 year cryopreserved cord blood. Blood, 2011;117:4773-7.
  12. Carroll J. Human cord blood for the hypoxic-ischemic neonate. Pediatr Res. 2012;71:459-63.
  13. Chhabra P, Brayman KL. Stem cell therapy to cure type 1 diabetes: from hype to hope. Stem Cells Transl Med. 2013;2:328-36. Review.
  14. Damien P, Allan D. Regenerative therapy and immune modulation using umbilical cord blood-derived cells. Biol Blood Marrow Transplant. 2015 Jun 12. pii: S1083-8791(15)00379-1. doi: 10.1016/j.bbmt.2015.05.022
  15. Ende M, Ende N. Hematopoietic transplantation by means of fetal (cord) blood. Virginia Med Mon. 1972;99:276–80.
  16. Escolar ML, Poe MD, Provenzale JM et al. Transplantation of umbilical cord blood in babies with infantile Krabbe’s disease. NEJM 2005; 352: 2069-2081.
  17. Fiorina P, Voltarelli J, Zavazava N. Immunological applications of stem cells in type 1 diabetes. Endocr Rev. 2011;32:725-54.
  18. Fruchtman SM, Hurlet A, Dracker R et al. The successful treatment of severe aplastic anemia with autologous cord blood transplantation. Biol Blood Marrow Transplant, 2004; 10: 741-2.
  19. Garbuzova-Davis S. et al. Human umbilical cord blood treatment in a mouse model of ALS: optimization of cell dose. PLoS ONE. 2008 June 25; 3(6).
  20. Gluckman E et al. Outcome of cord blood transplantation from related and unrelated donors. NEJM 1997;337:373-81
  21. Gluckman E, Broxmeyer HA, Auerbach AD, et al. Hematopoietic reconstitution in a patient with Fanconi’s anemia by means of umbilical-cord blood from HLA-identical sibling. N Engl J Med 1989; 79(7): 1874:1881.
  22. Gluckman E, Rocha V, Arcese W, Michael G, Sanz G, Chan KW et al. Factors associated with outcomes of unrelated cord blood transplant: guidelines for donor choice. Exp Hematol 2004; 32: 397-407.
  23. Gluckman E, Rocha V, Boyer-Chammard A, et al. Eurocord transplant Group and the European Blood and Marrow Transplantation Group. Outcome of cord-blood transplantation from related and unrelated donors. N Engl J Med. 1997;337(6):373-381.
  24. Goodwin HS, Bicknese AR, Chien SN, Bogucki BD, Quinn CO, Wall DA. Multilineage differentiation activity by cells isolated from umbilical cord blood: expression of bone, fat, and neural markers. Biol Blood Marrow Transplant. 2001;7:581-8
  25. Goulmy E et al. Mismatches of minor histocompatibility antigens between HLA_identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation. NEJM 1996;334:281-5
  26. Haller, M.J. et al. Autologous umbilical cord blood infusion for type 1 diabetes. Exp. Hematology. 2008; 36: 710-715.
  27. Harris D, Rogers I. Umbilical cord blood: a unique source of pluripotent stem cells for regenerative medicine. Curr Stem Cell Res Ther 2007; 2:301-309.
  28. Hong SH, Gang EJ, Jeong JA, et al. In vitro differentiation of human umbilical cord blood-derived mesenchymal stem cells into hepatocyte-like cells. Biochem Biophys Res Commun. 2005 May 20;330:1153-61
  29. https://clinicaltrials.gov/, accessed June 2015
  30. Huo W1, Liu X1, Tan C1, Han Y1, Kang C1, Quan W1, Chen J1. Stem cell transplantation for treating stroke: status, trends and development. Neural Regen Res. 2014 Sep 1;9(17):1643-8.
  31. Kurtzberg J et al. Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients. NEJM 1996;335:157-66
  32. Kurtzberg J, Prasad VK, Carter SL, et al. Results of the Cord Blood Transplantation Study: clinical outcomes of unrelated donor umbilical cord blood transplantation in pediatric patients with hematological malignancies. Blood 2008; 112: 4318-4327.
  33. Laporte JP et al. Cord blood transplantation from an unrelated donor in an adult with chronic myelogenous leukemia. NEJM 1996;335:373-81
  34. Laughlin MJ, Barker J, Bambach B, et al. Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors. N. Engl. J Med 2001; 344: 1815–1822.
  35. Liao W, Huang N, Yu J, Jares A, Yang J, Zieve G, Avila C, Jiang X, Zhang XB, Ma Y. Direct Conversion of Cord Blood CD34+ Cells Into Neural Stem Cells by OCT4. Stem Cells Transl Med. 2015 May 13. pii: sctm.2014-0289. [Epub ahead of print]
  36. Locatelli F et al. Related umbilical cord blood transplantation in patients with thalassemia and sickle cell disease. Blood 2003;101:2137-43
  37. Locatelli F, Kabbara N, Ruggeri A, et al. Outcome of patients with hemoglobinopathies given either cord blood or bone marrow transplantation from an HLA-identical sibling. Blood. 2013 May 21.
  38. Majhail N, Weisdorf D, Wagner J et al. Comparable results of umbilical cord blood and HLA-matched sibling donor preparative regimen for advanced Hodgkin lymphoma. Blood, 2006; 107: 3804-7.
  39. Min et al. Umbilical Cord Blood Therapy Potentiated with Erythropoietin for Children with Cerebral Palsy: A Double-blind, Randomized, Placebo-Controlled Trial Stem Cells 2013;31:581
  40. Parent’s Guide to Cord Blood Foundation. www.parentsguidetocordblood.org. 2007 – 2015
  41. Pozzobon et al. Fetal stem cells and skeletal muscle regeneration: a therapeutic approach. Ffront Aging Neurosci. 2014;222
  42. Rocha V1, Wagner JE Jr, Sobocinski KA, Klein JP, Zhang MJ, Horowitz MM, Gluckman E. Graft-versus-host disease in children who have received a cord-blood or bone marrow transplant from an HLA-identical sibling. Eurocord and International Bone Marrow Transplant Registry Working Committee on Alternative Donor and Stem Cell Sources. N Engl J Med. 2000 Jun 22;342(25):1846-54.
  43. Rocha V, Chastang C, Souillet G et al. Related cord blood transplants: the Eurocord experience from 78 transplants. Eurocord Transplant group, Bone Marrow Transplant, 1998; 21 (supple. 3): 559-62.
  44. Rosenkranz K, Meier C Umbilical cord blood cell transplantation after brain ischemia–from recovery of function to cellular mechanisms. Ann Anat. 2011;193:371-9.
  45. Rubinstein P et al. Outcomes among 562 recipients pf placental-blood transplants from unrelated donors. PNAS 1998;339:1565-77
  46. Rubinstein P, Carrier C, Scaradavou A, Kurtzberg J, Adamson J, Migliaccio AR, Berkowitz RL, Cabbad M, Dobrila NL, Taylor PE, Rosenfield RE, Stevens CE . Outcomes among 562 recipients of placental-blood transplants from unrelated donors. N Engl J Med. 1998 Nov 26;339(22):1565-77.
  47. Sandberg P et al. Umbilical cord blood derived stem cells and brain repair, Ann NY Acad Sci 2005: 1049:67-83.
  48. Shenoy S. Umbilical cord blood: an evolving stem cell source for sickle cell disease transplants. Stem Cells Transl Med. 2013;2:337-40.
  49. Sodian R1, Schaefermeier P, Abegg-Zips S, Kuebler WM, Shakibaei M, Daebritz S, Ziegelmueller J, Schmitz C, Reichart B. Use of human umbilical cord blood-derived progenitor cells for tissue-engineered heart valves. Ann Thorac Surg. 2010 Mar;89(3):819-28.
  50. Staba SL, Escolar ML, Poe M, et al. Cord blood transplants from unrelated donors in patients with Hurler’s syndrome. NEJM 2004; 305: 1960-1969
  51. Szabolcs P and Cairo MS. Unrelated umbilical cord blood transplantation and immune reconstitution. Semin Hematol. 2010 Jan;47(1):22-36
  52. Tse W and Laughlin M. Umbilical Cord Blood Transplantation: A New Alternative Option. Hematology Am Soc Hematol Educ Program. 2005;377-83
  53. Van Rood J, Stevens C, Smits J, Carrier C, Carpenter C, Scaradavou A. Reexposure of cord blood to noninherited maternal HLA antigens improves transplant outcome in haematological malignancies. Proc Natl Acad Sci 2009;106:19952-7
  54. Wagner J, Kernan N, Steinbuch M, et al. Allogeneic sibling umbilical cord blood transplantation in children with malignant and non-malignant disease. Lancet 1995; 346: 214 -219.
  55. Willing A, Eve D, Sanberg P. Umbilical cord blood transfusions for prevention of progressive brain injury and induction of neural recovery: an immunological perspective. Regen Med, 2007; 2:457-64
  56. World Marrow Donor Association (WMDA) Annual Report, 2006 – 2014
  57. Zhao Y1, Jiang Z, Zhao T, Ye M, Hu C, Yin Z, Li H, Zhang Y, Diao Y, Li Y, Chen Y, Sun X, Fisk MB, Skidgel R, Holterman M, Prabhakar B, Mazzone T Reversal of type 1 diabetes via islet β cell regeneration following immune modulation by cord blood-derived multipotent stem cells. BMC Med. 2012 Jan 10;10:3. doi: 10.1186/1741-7015-10-3.